Eli Lilly’s Mounjaro and Zepbound generated more than $5B in revenue last year and are on the way to becoming the bestselling pharmaceuticals of all time, Jessica Mendoza, Matt Kwong, and Peter Loftus of The Wall Street Journal reports. Now, the question is whether the company can keep its pace. Demand for the drugs are overwhelming during an ongoing shortage and the company is under pressure to develop an even more potent anti-obesity drug as competition mounts from rivals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA grants traditional approval to Lilly’s Retevmo for thyroid cancer
- Blue Cross Blue Shield of Michigan to drop weight loss drugs, Bloomberg says
- FDA AdCom on Eli Lilly’s donanemab better than anticipated, says Cantor
- Eli Lilly Stock (LLY) Gained on FDA Panel Approval
- FDA panel votes 11-0 Eli Lilly Alzheimer’s drug benefits outweigh risks